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Abstract: The role of the endothelin system, the functional counterpart of NO, in the pathophysiology
of polyglobulia remains still elusive. Therefore a novel erythropoietin overexpressing mouse was gener-
ated, with hematocrit levels of about 80%. Hence, we analyzed vascular contractions to ET-1 and big
endothelin-1 (big ET-1), endothelin-1 (ET-1) promoter activity, ET-1 immunochemistry, endothelin-1
(ET-1)-protein tissue levels, ETA/B-receptor mRNA expression in this novel transgenic model of severe
polyglobulia. For analysis of ET-1 promotor activity, EPO transgenic mice were mated with homozygous
transgenic mice expressing the lacZ gene under control of the human ET-1 promoter and immunochis-
tochemistry for gal blue was performed in lacZ transgenic animals. Notwithstanding markedly increased
eNOS expression, NO-mediated endothelium-dependent relaxation and circulating and vascular tissue
NO levels indicating enhanced bioavailability of NO, ET-1 tissue levels were also augmented in heart,
kidney, liver and aorta (2.2±0.3 vs. 0.5±0.1 pg/mg tissue; P<0.01) of transgenic polyglobulic animals.
Accordingly, immunohistochemistry demonstrated enhanced expression of ET-1 protein in the vascular
wall of polyglobulic animals as compared to controls (p< 0.05), while increase of ET-1 promoter activity
was confined to the perivascular tissue (P<0.05). NOS inhibition with L-NAME unmasked increased vas-
cular reactivity to ET-1 and bigET-1 and aortic ETA/B receptor mRNA gene expression was enhanced
(p<0.05 vs. controls). Administration of the NOS inhibitor L-NAME led to acute vasoconstriction of
peripheral resistance vessels, hypertension and death of transgenic mice within 2 days, while wildtypes
did not show increased mortality. Treatment with the ETA antagonist darusentan doubled survival time
of transgenic polyglobulic mice after NO synthase inhibition (p<0.01 vs placebo). In conclusion, in this
study we provide first evidence that the tissue endothelin system is activated by polyglobulia. Together
with a stimulated NO system it contributes to cardiovascular regulation in pathophysiological conditions
associated with increased hematocrit
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The role of the endothelin system, the functional counterpart of NO, in
the pathophysiology of polyglobulia remains still elusive. Therefore a
novel erythropoietin overexpressing mouse was generated, with hemat-
ocrit levels of about 80%.
Hence, we analyzed vascular contractions to ET-1 and big endothe-
lin-1 (big ET-1), endothelin-1 (ET-1) promoter activity, ET-1 immuno-
chemistry, endothelin-1 (ET-1)-protein tissue levels, ETA/B-receptor
mRNA expression in this novel transgenic model of severe polyglobulia.
For analysis of ET-1 promotor activity, EPO transgenic mice were mated
with homozygous transgenic mice expressing the lacZ gene under control
of the human ET-1 promoter and immunochistochemistry for gal blue
was performed in lacZ transgenic animals.
Notwithstanding markedly increased eNOS expression, NO-mediated
endothelium-dependent relaxation and circulating and vascular tissue NO
levels indicating enhanced bioavailability of NO, ET-1 tissue levels were
also augmented in heart, kidney, liver and aorta (2.20.3 vs. 0.50.1
pg/mg tissue; P0.01) of transgenic polyglobulic animals. Accordingly,
immunohistochemistry demonstrated enhanced expression of ET-1 pro-
tein in the vascular wall of polyglobulic animals as compared to controls
(p 0.05), while increase of ET-1 promoter activity was confined to the
perivascular tissue (P0.05). NOS inhibition with L-NAME unmasked
increased vascular reactivity to ET-1 and bigET-1 and aortic ETA/B
receptor mRNA gene expression was enhanced (p0.05 vs. controls).
Administration of the NOS inhibitor L-NAME led to acute vasoconstric-
tion of peripheral resistance vessels, hypertension and death of transgenic
mice within 2 days, while wildtypes did not show increased mortality.
Treatment with the ETA antagonist darusentan doubled survival time of
transgenic polyglobulic mice after NO synthase inhibition (p0.01 vs
placebo).
In conclusion, in this study we provide first evidence that the tissue
endothelin system is activated by polyglobulia. Together with a stimu-
lated NO system it contributes to cardiovascular regulation in pathophys-
iological conditions associated with increased hematocrit.
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EXPERIMENTAL HEART FAILURE DUE TO
AORTOCAVAL SHUNT: ROLE OF KININS AND ANP
Hector Nolly, Belisario Fernandez, Mariela Nolly. Hypertension
Center, Mendoza and Faculty of Pharm and Biochem (UBA),
Argentina.
Angiotensin II (AII) has been implicated as a pathogenetic factor in
hypertension (HT) and therefore blockade of the AT1 angiotensin recep-
tor has been considered a therapeutic approach to treat hypertension. The
AT1 receptor is responsible for the majority of the known effects of AII;
however, the role of AT2 receptor is less well defined. We hypothesized
that blockade of AT1 receptors increases AII levels, which in turn
activates the AT2 receptor and through a kinin pathway induces cardio-
protection. In addition, we investigate whether or not AII modulates the
release of ANP in rats with aortocaval shunt.
Fifty male Wistar rats (15030g) were used. To induce heart failure,
we relied on the aortocaval shunt, an established model of moderate
high-output heart failure. Cardiac mass and plasma ANP and cardiac
kininogenase activity were estimated.
Treatment with AT1 receptor antagonist Telmisartan significantly
(p0.01) increased kininogenase activity (from 22014pg/mg to
158042) and plasma levels of ANP (from 485pg/ml to 32216).
Treatment with Telmisartan significantly (p0.01) prevent cardiac mass
increase and this effect was blunted by the kinin B2 receptor antagonist,
icatibant and by the AT2 receptor antagonist PD123319.
Our results suggest that the AII-mediated stimulation of the AT2
receptor alone and/or through the release of kinins may be an important
component of the cardioprotective effect of Telmisartan, perhaps acting
via release of nitric oxide (NO) or by hyperpolarization caused by
activation of potassium channels.
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AUTOMATED VERSUS OPERATOR DIRECTED
DIAMETER MEASUREMENTS FOR ENDOTHELIAL
FUNCTION IN HYPERTENSIVE PATIENTS
George A. Mansoor, William B. White. Medicine, University of
Connecticut Health Center, Farmington, CT, United States.
Endothelial function (EF) measured by either coronary or peripheral
arterial evaluation is an important prognostic marker for future cardio-
vascular events. However, these traditional arterial methods are invasive
and carry a risk of injury to subjects. Flow-mediated brachial artery
dilation (FMD) has emerged as a nitric oxide dependent method to
measure EF in hypertensive subjects. Despite its relative safety, one
major limitation of FMD is the limited quality of ultrasound images with
poor delineation of vessel walls and M-lines. Traditionally, operator
directed manual measurements of FMD are made on these ultrasound
images but are very subjective and tedious. We postulated that automatic
edge detection image analysis is superior to operator directed measure-
ments of arterial diameter. We therefore examined the intra-observer
repeatability of manual vessel diameter measurements versus automated
edge detection based measurements in hypertensive subjects. Twenty
ultrasound images of brachial arteries captured during FMD testing were
selected to ensure variation of image quality and baseline vessel diameter
and compared manual measurements and edge detection methods (Image
Pro plus v4, Media Cybernetics, Silver Spring, MD). A single expert
operator performed all measurements by selecting the area of interest and
doing 5 manual measurements and 1 edge detection measurement on two
occasions. We compared the 2 methods using Bland -Altman limits of
agreement. The 20 images ranged in diameter from 3.14 mm to 5.67 mm.
The two types of measurements had a significant correlation (R0.94,
P.0001), while the differences of the measurements had no correlation
(R.082, P.92). The automated method had significantly narrower
limits of agreement than the manual method. There was no linear rela-
tionship of the differences to the absolute vessel diameter.[table]Auto-
mated edge detection is superior to operator directed brachial artery
diameter measurements. This superiority of automated edge tracing over
manual measurements will likely allow the detection of smaller changes
in FMD in research studies.
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METHOD OF
MEASUREMENT Mean difference 2 standard deviation
MANUAL 0.039 0.54 to 0.46
AUTOMATIC 0.009 0.19 to 0.21
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